Conditions: Non-Small Cell Lung Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 51
Healthy volunteers: no

Brief summary:
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based chemotherapy without progression. Patients will receive Tarceva at a dose of 150 mg orally daily until disease progression or unacceptable toxicity occurs.

Detailed description:

Arms:
arm 1: Participants received erlotinib 150 mg orally once a day for 48 weeks.

Interventions: intervention 1: Erlotinib
Intervention descriptions: intervention 1: Erlotinib was supplied as tablets.

Protocol document: